Table 2.
Characteristics of patients treated by trial participants, stratified by exposure and period
| Control | Digital Behavior Change Interventions | |||
|---|---|---|---|---|
|
| ||||
| Pre-trial (n=113) | Post-trial (n=156) | Pre-trial (n=154) | Post-trial (n=134) | |
| Age – years (mean [SD]) | 80(11.3) | 81 (9.4) | 79 (13.0) | 79 (10.8) |
| Sex – male (n, %) | 52 (46) | 82 (53) | 66 (43) | 73 (54) |
| Race (n, %) | ||||
| White | 89 (79) | 133 (85) | 131 (85) | 105 (78) |
| Black | 11 (10) | 8 (5) | 7 (5) | 11 (8) |
| Asian | 6 (5) | 5 (3) | 9 (6) | 7 (5) |
| Hispanic | 4 (4) | 5 (3) | 0 (0) | 6 (4) |
| Native American, Pacific Islander | 0 (0) | 1 (0.6) | 0 (0) | 0 (0) |
| Other | 3 (3) | 4 (3) | 7 (5) | 5 (4) |
| Number of comorbidities, median (IQR) | 3 (1–6) | 4 (2–5) | 4 (3–6) | 4 (2–6) |
| Selected comorbidities | ||||
| Congestive heart failure | 25 (22) | 28 (18) | 21 (14) | 17 (13) |
| Cardiac arrhythmias | 41 (36) | 59 (38) | 56 (36) | 39 (29) |
| Renal failure | 25 (22) | 30 (19) | 38 (25) | 25 (19) |
| Liver disease | 2 (2) | 8 (5) | 8 (5) | 3 (2) |
| Lymphoma | 2 (2) | 3 (2) | 3 (2) | 1 (1) |
| Metastatic cancer | 2 (2) | 2 (1) | 4 (3) | 4 (3) |
| Solid tumor without metastasis | 7 (6) | 7 (4) | 4 (3) | 4 (3) |
| Coagulopathy | 20 (18) | 14 (9) | 19 (12) | 15 (11) |
| Weight loss | 11 (10) | 16 (10) | 16 (10) | 16 (12) |
| Fluid/electrolyte disorders | 34 (30) | 58 (37) | 69 (45) | 55 (41) |
| ISS (median, IQR) | 16 (16–20) | 17 (16–17) | 16 (16–17) | 16 (16–17) |
| Injury patterns | ||||
| AIS head≥3 (n, %) | 88 (78) | 122 (78) | 120 (78) | 107 (80) |
| AIS face≥3 (n, %) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| AIS chest≥ 3 (n, %) | 3 (3) | 7 (4) | 7 (5) | 3 (2) |
| AIS abdomen≥3 (n, %) | 2 (2) | 1 (1) | 5 (3) | 0 (0) |
| AIS extremities/pelvis ≥3 (n, %) | 5 (4) | 8 (4) | 12 (8) | 3 (2) |
| AIS external≥3 (n, %) | 0 (0) | 0 (0) | 1 (1) | 0 (0) |